{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:26:01Z","timestamp":1792106761534,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10067-021-05746-z","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T14:03:26Z","timestamp":1619705006000},"page":"4007-4017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Iguratimod combination therapy compared with methotrexate monotherapy for the treatment of rheumatoid arthritis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Sajan","family":"Shrestha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"issue":"9","key":"5746_CR1","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Alteha","year":"2010","unstructured":"Alteha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham Iii CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569\u20132581","journal-title":"Arthritis Rheum"},{"issue":"3","key":"5746_CR2","first-page":"S18","volume":"28","author":"J Smolen","year":"2010","unstructured":"Smolen J, Aletaha D (2010) The assessment of disease activity in rheumatoid arthritis. Clin Exp Rheumatol 28(3):S18\u2013S27","journal-title":"Clin Exp Rheumatol"},{"key":"5746_CR3","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, Mcinnes IB, Solomon DH, Strand V, Yamamoto K (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001. https:\/\/doi.org\/10.1038\/nrdp.2018.1","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"5746_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, Van Vollenhoven R (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960\u2013977","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"5746_CR5","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360\u20131372","journal-title":"JAMA"},{"issue":"5","key":"5746_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1586\/1744666X.2015.1027151","volume":"11","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Yamaguchi T, Hara M (2015) Iguratimod for the treatment of rheumatoid arthritis in Japan. Expert Rev Clin Immunol 11(5):565\u2013573","journal-title":"Expert Rev Clin Immunol"},{"key":"5746_CR7","doi-asserted-by":"publisher","unstructured":"Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, Jung SM, Kishimoto M, Kumar A, Leong KP (2019) 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 22(3):357-375. 7. https:\/\/doi.org\/10.1111\/1756-185X.13513","DOI":"10.1111\/1756-185X.13513"},{"issue":"6","key":"5746_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S0022-2143(99)90186-5","volume":"133","author":"A Kawakami","year":"1999","unstructured":"Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A, Aoyagi T, Furuichi I, Nakashima T, Migita K (1999) Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med 133(6):566\u2013574","journal-title":"J Lab Clin Med"},{"issue":"12","key":"5746_CR9","first-page":"2591","volume":"28","author":"M Kohno","year":"2001","unstructured":"Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, Inoue K, Kusaka Y, Kondo M, Sano H (2001) Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol 28(12):2591\u20132596","journal-title":"J Rheumatol"},{"issue":"10","key":"5746_CR10","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.4049\/jimmunol.1300832","volume":"191","author":"Q Luo","year":"2013","unstructured":"Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao F, Gu Y, Wu X, Shen Y, Xu Q (2013) A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol 191(10):4969\u20134978","journal-title":"J Immunol"},{"key":"5746_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/214683","volume":"2015","author":"Y Wei","year":"2015","unstructured":"Wei Y, Sun X, Hua M, Tan W, Wang F, Zhang M (2015) Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-induced RANKL\/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients. Biomed Res Int 2015:1\u20138. https:\/\/doi.org\/10.1155\/2015\/214683","journal-title":"Biomed Res Int"},{"issue":"11","key":"5746_CR12","first-page":"649","volume":"15","author":"K Tanaka","year":"1992","unstructured":"Tanaka K, Aikawa Y, Kawasaki H, Asaoka K, Inaba T, Yoshida C (1992) Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6. Aust J Pharm 15(11):649\u2013655","journal-title":"Aust J Pharm"},{"issue":"8","key":"5746_CR13","doi-asserted-by":"publisher","first-page":"e0202601","DOI":"10.1371\/journal.pone.0202601","volume":"13","author":"N Tokai","year":"2018","unstructured":"Tokai N, Yoshida S, Kotani T, Yoshikawa A, Kimura Y, Fujiki Y, Matsumura Y, Takeuchi T, Makino S, Arawaka S (2018) Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis. PLoS One 13(8):e0202601","journal-title":"PLoS One"},{"issue":"11","key":"5746_CR14","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/rheumatology\/keg381","volume":"42","author":"K Tanaka","year":"2003","unstructured":"Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, Muraguchi A (2003) Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology 42(11):1365\u20131371","journal-title":"Rheumatology"},{"issue":"12","key":"5746_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.14715\/cmb\/2016.62.13.8","volume":"62","author":"X Wang","year":"2016","unstructured":"Wang X, Li P, Xu T, Ding R, Zhang X, Bi L (2016) Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1\u03b2-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cell Mol Biol 62(12):44\u201350","journal-title":"Cell Mol Biol"},{"key":"5746_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/4901591","volume":"2018","author":"JL Song","year":"2018","unstructured":"Song JL, Liu HL, Zhu Q, Miao YT, Wang FY, Yang F, Cheng WJ, Xi YB, Niu XY, He DY (2018) T-614 Promotes osteoblastic cell differentiation by increasing Dlx5 expression and regulating the activation of p38 and NF-\u03baB. Biomed Res Int 2018:1\u20138. https:\/\/doi.org\/10.1155\/2018\/4901591","journal-title":"Biomed Res Int"},{"key":"5746_CR17","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s10067-020-04986-9","volume":"39","author":"S Shrestha","year":"2020","unstructured":"Shrestha S, Zhao J, Yang C, Zhang J (2020) Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 39:2139\u20132150. https:\/\/doi.org\/10.1007\/s10067-020-04986-9","journal-title":"Clin Rheumatol"},{"key":"5746_CR18","doi-asserted-by":"publisher","unstructured":"Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ, Bombardier C (2016) Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis. Cochrane Database Syst Rev 8. https:\/\/doi.org\/10.1002\/14651858.CD010227.pub2","DOI":"10.1002\/14651858.CD010227.pub2"},{"key":"5746_CR19","first-page":"2069","volume":"67","author":"ME Orme","year":"2015","unstructured":"Orme ME, Hawes C, Mitchell SA (2015) Systematic review and network meta-analysis of combination treatments in disease modifying anti-rheumatic drug experienced patients with severe rheumatoid arthritis: analysis of American College of Rheumatology Criteria Scores 20, 50, and 70: An Update: abstract Number: 1676. Arthritis Rheum 67:2069\u20132071","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5746_CR20","first-page":"409","volume":"21","author":"F Buckley","year":"2015","unstructured":"Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP (2015) Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm 21(5):409\u2013423","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"5746_CR21","doi-asserted-by":"publisher","first-page":"e106408","DOI":"10.1371\/journal.pone.0106408","volume":"9","author":"N Graudal","year":"2014","unstructured":"Graudal N, Hubeck-Graudal T, Tarp S, Christensen R, J\u00fcrgens G (2014) Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials. PLoS One 9(9):e106408","journal-title":"PLoS One"},{"issue":"11","key":"5746_CR22","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1093\/rheumatology\/kei031","volume":"44","author":"E Choy","year":"2005","unstructured":"Choy E, Smith C, Dore C, Scott D (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 44(11):1414\u20131421","journal-title":"Rheumatology"},{"key":"5746_CR23","doi-asserted-by":"publisher","unstructured":"Katchamart W, Trudeau J, Phumethum V, Bombardier C (2010) Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 4. https:\/\/doi.org\/10.1002\/14651858.CD008495","DOI":"10.1002\/14651858.CD008495"},{"issue":"2","key":"5746_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/14397595.2014.938401","volume":"25","author":"K Okamura","year":"2015","unstructured":"Okamura K, Yonemoto Y, Okura C, Kobayashi T, Takagishi K (2015) Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Mod Rheumatol 25(2):235\u2013240","journal-title":"Mod Rheumatol"},{"issue":"4","key":"5746_CR25","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3109\/14397595.2014.998361","volume":"25","author":"K Okamura","year":"2015","unstructured":"Okamura K, Yonemoto Y, Suto T, Okura C, Takagishi K (2015) Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol 25(4):534\u2013539","journal-title":"Mod Rheumatol"},{"key":"5746_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2018.1510879","volume":"29","author":"T Suto","year":"2018","unstructured":"Suto T, Yonemoto Y, Okamura K, Sakane H, Takeuchi K, Tamura Y, Kaneko T, Ayabe K, Chikuda H (2018) The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis. Mod Rheumatol 29:1\u20137. https:\/\/doi.org\/10.1080\/14397595.2018.1510879","journal-title":"Mod Rheumatol"},{"issue":"2","key":"5746_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14397595.2017.1336865","volume":"28","author":"A Yoshikawa","year":"2018","unstructured":"Yoshikawa A, Yoshida S, Kimura Y, Tokai N, Fujiki Y, Kotani T, Matsumura Y, Takeuchi T, Makino S (2018) Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: a retrospective study. Mod Rheumatol 28(2):227\u2013234","journal-title":"Mod Rheumatol"},{"issue":"6","key":"5746_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727\u2013735","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"5746_CR29","first-page":"29","volume":"10","author":"JP Higgins","year":"2016","unstructured":"Higgins JP, Sterne JA, Savovic J, Page MJ, Hr\u00f3bjartsson A, Boutron I, Reeves B, Eldridge S (2016) A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev 10(Suppl 1):29\u201331","journal-title":"Cochrane Database Syst Rev"},{"key":"5746_CR30","unstructured":"Review Manager 5 (RevMan 5) (2014). vol 5.3. Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen"},{"issue":"7454","key":"5746_CR31","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"Group GW","year":"2004","unstructured":"Group GW (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490","journal-title":"BMJ"},{"key":"5746_CR32","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University (developed by Evidence Prime), Hamilton (ON)"},{"issue":"8","key":"5746_CR33","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s00393-015-1641-y","volume":"75","author":"Z Xia","year":"2016","unstructured":"Xia Z, Lyu J, Hou N, Song L, Li X, Liu H (2016) Iguratimod in combination with methotrexate in active rheumatoid arthritis. Z Rheumatol 75(8):828\u2013833. https:\/\/doi.org\/10.1007\/s00393-015-1641-y","journal-title":"Z Rheumatol"},{"issue":"5","key":"5746_CR34","first-page":"2353","volume":"28","author":"L Zhao","year":"2017","unstructured":"Zhao L, Jiang ZY, Zhang YD, Ma HS, Cai CL (2017) Analysis of efficacy and safety of treatment of active rheumatoid arthritis with iguratimod and methotrexate. Biomed Res Int 28(5):2353\u20132359","journal-title":"Biomed Res Int"},{"issue":"3","key":"5746_CR35","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3109\/s10165-012-0724-8","volume":"23","author":"N Ishiguro","year":"2013","unstructured":"Ishiguro N, Yamamoto K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Hara M (2013) Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 23(3):430\u2013439","journal-title":"Mod Rheumatol"},{"issue":"9","key":"5746_CR36","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10067-015-2999-6","volume":"34","author":"XW Duan","year":"2015","unstructured":"Duan XW, Zhang XL, Mao SY, Shang JJ, Shi XD (2015) Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin Rheumatol 34(9):1513\u20131519","journal-title":"Clin Rheumatol"},{"issue":"6","key":"5746_CR37","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s10067-017-3668-8","volume":"36","author":"XT Wang","year":"2017","unstructured":"Wang XT, Ma CL, Li P, Zhao F, Bi LQ (2017) Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis. Clin Rheumatol 36(6):1369\u20131377","journal-title":"Clin Rheumatol"},{"issue":"7","key":"5746_CR38","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3969\/j.issn.1005-4561.2018.07.010","volume":"28","author":"J Chen","year":"2018","unstructured":"Chen J, Ding Z, Liu J (2018) Effects of iguratimod combined with methotrexate on serum inflammatory factors and bone metabolism in patients with rheumatoid arthritis. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine (Zhejiang Zhong xi yi jie he za zhi) 28(7):552\u2013555. https:\/\/doi.org\/10.3969\/j.issn.1005-4561.2018.07.010","journal-title":"Zhejiang Journal of Integrated Traditional Chinese and Western Medicine (Zhejiang Zhong xi yi jie he za zhi)"},{"issue":"03","key":"5746_CR39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3969\/j.jssn.1674-2257.2018.03.020","volume":"13","author":"S Li","year":"2018","unstructured":"Li S (2018) Clinical efficacy of iguratimod in the treatment of the moderate and severe rheumatoid arthritis and its effect on bone metabolism. Journal of Chengdu Medical College 13(03):327\u2013331. https:\/\/doi.org\/10.3969\/j.jssn.1674-2257.2018.03.020","journal-title":"Journal of Chengdu Medical College"},{"issue":"03","key":"5746_CR40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.13699\/j.cnki.1001-6821.2019.03.011","volume":"35","author":"LH Wang","year":"2019","unstructured":"Wang LH, Liu SX, Chen R, Fu K (2019) Clinical trial of methotrexate tablets combined with iguratimod tablets in the treatment of rheumatoid arthritis. The Chinese Journal of Clinical Pharmacology (Zhongguo lin chuang yao li xue za zhi) 35(03):231\u2013234. https:\/\/doi.org\/10.13699\/j.cnki.1001-6821.2019.03.011","journal-title":"The Chinese Journal of Clinical Pharmacology (Zhongguo lin chuang yao li xue za zhi)"},{"issue":"12","key":"5746_CR41","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3969\/j.issn.10010057.2015.12.014","volume":"32","author":"YM Xiong","year":"2015","unstructured":"Xiong YM, Fan SN, Zou L (2015) Study on the effect of iguratimod combined with methotrexate on the anti-guanine peptide antibody and other indicators in patients with rheumatoid arthritis. J Clin Med 32(12):833\u2013835. https:\/\/doi.org\/10.3969\/j.issn.10010057.2015.12.014","journal-title":"J Clin Med"},{"issue":"01","key":"5746_CR42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7619\/jcmp.201501038","volume":"19","author":"BJ Xu","year":"2015","unstructured":"Xu BJ, Mo SQ, Xue XQ (2015) Clinical effect of methotrexate combined with iguratimod on treatment of rheumatoid arthritis. J Clin Med Pract 19(01):120\u2013122. https:\/\/doi.org\/10.7619\/jcmp.201501038","journal-title":"J Clin Med Pract"},{"issue":"08","key":"5746_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.19347\/j.cnki.2096-1413.2016.08.015","volume":"01","author":"FW Ye","year":"2016","unstructured":"Ye FW, Zhu YY, Wu LY, Shen W (2016) Clinical observation of iguratimod combined with methotrexate in the treatment of refractory rheumatoid arthritis. Clinical Research and Practice 01(08):24. https:\/\/doi.org\/10.19347\/j.cnki.2096-1413.2016.08.015","journal-title":"Clinical Research and Practice"},{"issue":"05","key":"5746_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3760\/cma.J.jssn.1673-4904.2016.05.017","volume":"39","author":"WM Zhao","year":"2016","unstructured":"Zhao WM, Yao DY, Huo HS, Qin CM, Wei QJ (2016) Clinical study of iguratimod in the treatment of active rheumatoid arthritis. Chin J Postgraduates Med 39(05):450\u2013452. https:\/\/doi.org\/10.3760\/cma.J.jssn.1673-4904.2016.05.017","journal-title":"Chin J Postgraduates Med"},{"issue":"9","key":"5746_CR45","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/annrheumdis-2013-205079","volume":"74","author":"MM Ward","year":"2015","unstructured":"Ward MM, Guthrie LC, Alba MI (2015) Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Ann Rheum Dis 74(9):1691\u20131696","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"5746_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.19347\/j.cnki.2096-1413.201815020","volume":"3","author":"HN Zhao","year":"2018","unstructured":"Zhao HN, Xia JH (2018) Clinical effect of iguratimod combined with methotrexate in the treatment of rheumatoid arthritis. Clinical Research and Practice 3(15):44\u201345. https:\/\/doi.org\/10.19347\/j.cnki.2096-1413.201815020","journal-title":"Clinical Research and Practice"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05746-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05746-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05746-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T22:00:24Z","timestamp":1632520824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05746-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5746"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05746-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"6 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}